These findings support the therapeutic rationale for investigating asparaginase—alone or combined with ASNS inhibitors or mTOR antagonists—in ASNS-high SCLC, particularly for relapsed/refractory disease where patient stratification by ASNS status could identify responsive subsets [50,53,55]. This evidence concerns the gene MTOR and small cell lung carcinoma.